The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients DOI Creative Commons

Yibin Zhang,

Xiao-xing Liao,

Jialu Xu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2783 - 2783

Published: Dec. 6, 2024

Type 2 diabetes mellitus (T2DM), accounting for the majority of prevalence, is associated with an increased risk cognition decline and deterioration function in diabetic patients. The sodium–glucose cotransporter (SGLT2), located renal proximal tubule, plays a role urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac improvement preventing treating cognitive impairment (CI), including mild impairment, Alzheimer’s disease vascular dementia T2DM Studies suggest that SGLT2i may ameliorate CI through metabolism pathways, inflammation, oxidative stress, neurotrophic factors AChE inhibition. Clinical trials meta-analyses reported significant insignificant results. Given their effects, offer unique protection against CI. This review compiles mechanisms clinical evidence, emphasizing need future analysis, evaluation, to verify recommend optimal selection dosage specific

Language: Английский

Effect of ultra-high pressure combined with heat-assisted treatment on the characterization, moisture absorption, and antioxidant activity properties of walnut peptide DOI
Xichun Sheng, Mengxiong Sun, Yaoxin Zhang

et al.

Food Chemistry, Journal Year: 2025, Volume and Issue: unknown, P. 143473 - 143473

Published: Feb. 1, 2025

Language: Английский

Citations

0
Molecular Mechanisms of Dietary Bioactive Peptides in Treating Alzheimer’s Disease and Mild Cognitive Impairment by Network Pharmacology and Molecular Docking Analysis DOI
Ruirui Li, Jing Zi, Y. Hu

et al.

Rejuvenation Research, Journal Year: 2025, Volume and Issue: unknown

Published: March 13, 2025

Emerging evidence suggests that bioactive peptides from various foods have therapeutic potentials in improving cognitive function Alzheimer's disease (AD) and mild impairment (MCI). We aimed to explore the characteristics of these their mechanisms on AD/MCI using a network pharmacology approach. compiled dataset cognition-enhancing literatures identified shared targets between Swiss Target Predication, PharmMapper, OMIM, GeneCards, TTD, Drugbank databases. then performed functional enrichment analysis constructed gene–gene interaction identify key hub targets. Additionally, we investigated transcription factors (TFs) microRNAs (miRNAs) regulating genes. Molecular docking dynamic simulations were AutoDock Vina GROMACS. 59 oligopeptides, typically short rich arginine. These predicted interact with 222 potential relevant AD/MCI, pathways mainly involving neuroactive ligand-receptor interactions inflammation. 15 targets, regulated by 144 TFs 95 miRNAs. Notably, containing "Trp-Tyr" sequence demonstrated strong binding affinities many especially matrix metalloproteinase-9. The findings provided valuable insights into molecular through which may act against highlight for future exploration natural foods.

Language: Английский

Citations

0
Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances DOI Creative Commons
Xue Chen,

Qingfei Chu,

Qingmiao Shi

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: April 4, 2025

Language: Английский

Citations

0
The Promising Potency of Sodium–Glucose Cotransporter 2 Inhibitors in the Prevention of and as Treatment for Cognitive Impairment Among Type 2 Diabetes Patients DOI Creative Commons

Yibin Zhang,

Xiao-xing Liao,

Jialu Xu

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(12), P. 2783 - 2783

Published: Dec. 6, 2024

Type 2 diabetes mellitus (T2DM), accounting for the majority of prevalence, is associated with an increased risk cognition decline and deterioration function in diabetic patients. The sodium–glucose cotransporter (SGLT2), located renal proximal tubule, plays a role urine glucose reabsorption. SGLT2 inhibitors (SGLT2i), have shown potential benefits beyond cardiac improvement preventing treating cognitive impairment (CI), including mild impairment, Alzheimer’s disease vascular dementia T2DM Studies suggest that SGLT2i may ameliorate CI through metabolism pathways, inflammation, oxidative stress, neurotrophic factors AChE inhibition. Clinical trials meta-analyses reported significant insignificant results. Given their effects, offer unique protection against CI. This review compiles mechanisms clinical evidence, emphasizing need future analysis, evaluation, to verify recommend optimal selection dosage specific

Language: Английский

Citations

0